2024-10-13 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis Report

**Company Overview:** Amgen Inc. is a leading biotechnology company developing and producing human therapeutics.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return (AMGN):** 83.62%
* **Cumulative Return (VOO):** 135.82%
* **Performance Gap:** -52.2%
* **Relative Divergence:** 33.78% (This means that AMGN's performance is currently at the 33.78% percentile of its historical performance range relative to VOO.)

**2. Recent Price Action:**

* **Closing Price:** $328.35
* **5-Day Moving Average:** $321.38
* **20-Day Moving Average:** $325.42
* **60-Day Moving Average:** $327.48

**3. Technical Indicators:**

* **RSI:** 44.49 (Neutral: neither overbought nor oversold)
* **PPO:** 0.05 (Slight upward momentum)
* **Delta_Previous_Relative_Divergence:** -9.01 (Short-term downtrend)
* **Expected Return:** 0.0% (This represents a 5-year expected return compared to the S&P 500, taking into account potential outperformance.)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

**Analysis:** 
* AMGN's most recent earnings for the quarter ending August 2024 were $1.39 per share, exceeding analyst expectations of $1.36.
* Revenue also surpassed expectations, reaching $8.39 billion compared to the projected $8.34 billion.
* Overall, AMGN delivered a strong quarter with both EPS and revenue surpassing expectations, indicating robust growth momentum.

**5. News and Recent Issues:**

**Recent Market Outlook for AMGN:**
* **Analyst Opinions:** 
    * Many analysts remain positive on AMGN's long-term prospects, citing its strong product portfolio and pipeline. 
    * They highlight the company's solid financial position, with a focus on its high dividend yield.
* **Performance Highlights:** 
    * AMGN has been a consistent performer in the biotechnology sector. 
    * The company's efforts in developing innovative therapies for chronic diseases continue to drive its success.

**Recent Issues:** 
* **Biosimilar competition:** AMGN faces pressure from biosimilars entering the market, which can impact its sales. 
* **Pricing pressures:** The company has been facing pricing pressures from payers, which can impact its revenue and margins.

**6. Overall Analysis:**

AMGN is a mature biotechnology company with a strong financial position. While its growth has slowed down in recent years due to biosimilar competition, the company's product portfolio and pipeline remain robust, potentially driving future growth. The recent strong earnings results offer further confidence in AMGN's ability to outperform in the coming years.

**7. Summary:**

Amgen Inc. (AMGN) is a leading biotechnology company with a solid track record of delivering consistent growth. The company's recent earnings results are encouraging, but the long-term outlook is slightly uncertain due to ongoing biosimilar competition and pricing pressures. However, its strong financial position and focus on innovation remain key strengths. Based on current market conditions and analyst expectations, AMGN presents a potential long-term investment opportunity for investors seeking growth and dividends. 
